1. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens 
Mark H. Eckman, John W. Ward, Kenneth E. Sherman 
Clinical Gastroenterology and Hepatology 
Volume 17, Issue 5, Pages e9 (April 2019)
DOI: /j.cgh
Copyright © 2019 AGA Institute Terms and Conditions

2. Figure 1
One-way sensitivity analysis examining the ICER of universal screening compared with no screening, as a function of the prevalence of HCV-antibody positivity in the general population. K$/QALY, signifies thousands of dollars/quality-adjusted life year.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

3. Figure 2
One-way sensitivity analysis examining the ICER of universal screening compared with birth cohort screening, as a function of the prevalence of HCV-antibody positivity in adults who are not members of the birth cohort born between 1945 and Above a prevalence of 0.07%, universal screening costs less than $50,000 per QALY compared with birth cohort screening.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

4. Figure 3
One-way sensitivity analysis examining monthly cost of DAA agent. The base-case value for this parameter is $8090. Below a monthly cost of roughly $2500, universal screening dominates, being less costly and more effective than birth cohort screening.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

5. Figure 4
Tornado diagram of 1-way sensitivity analyses for the strategy of universal screening compared with birth cohort screening. The ICER, in dollars per QALY (horizontal axis) ranges between minus $10,000 and $100,000/QALY. For each parameter, the upper and lower limits of the sensitivity analysis are based on either the 95% CIs, or a clinically reasonable range. A negative ICER indicates that the strategy is less expensive and more effective than its competitor. The base-case result is marked by the dotted line at the center of the tornado plot. Parameters at the top of the figure (wide mouth of the tornado) have a larger impact on the ICER within their 95% CIs or clinically plausible range. EIA, ELISA.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

6. Supplementary Figure 1
(A) Decision tree model. (B) Markov model. AB, antibody; EIA, ELISA; PCR, polymerase chain reaction; RAS, resistance associated substitution; Rx, treatment; s/p, status post.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

7. Supplementary Figure 2 State transitions for Metavir fibrosis stages.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

8. Supplementary Figure 3
Seed distributions of Metavir fibrosis stages at beginning of Markov simulation.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

9. Supplementary Figure 4
Natural history of chronic hepatitis C infection - health state transitions across lifetime. HCC, hepatocellular carcinoma; s/p, status post.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

10. Supplementary Figure 5
Cumulative probability of complications of end-stage liver disease. HCC, hepatocellular carcinoma.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

11. Supplementary Figure 6 Cost-effectiveness acceptability curve.
Clinical Gastroenterology and Hepatology  , e9DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions